Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$458.3 million.
- Keros Therapeutics' Retained Earnings rose 1232.88% to -$458.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$458.3 million, marking a year-over-year increase of 1232.88%. This contributed to the annual value of -$568.8 million for FY2024, which is 4911.91% down from last year.
- As of Q3 2025, Keros Therapeutics' Retained Earnings stood at -$458.3 million, which was up 1232.88% from -$451.0 million recorded in Q2 2025.
- Keros Therapeutics' 5-year Retained Earnings high stood at -$80.9 million for Q1 2021, and its period low was -$568.8 million during Q4 2024.
- Over the past 5 years, Keros Therapeutics' median Retained Earnings value was -$301.7 million (recorded in 2023), while the average stood at -$303.8 million.
- In the last 5 years, Keros Therapeutics' Retained Earnings crashed by 15647.07% in 2021 and then soared by 1232.88% in 2025.
- Over the past 5 years, Keros Therapeutics' Retained Earnings (Quarter) stood at -$123.8 million in 2021, then crashed by 84.59% to -$228.4 million in 2022, then plummeted by 66.97% to -$381.4 million in 2023, then crashed by 49.12% to -$568.8 million in 2024, then grew by 19.42% to -$458.3 million in 2025.
- Its last three reported values are -$458.3 million in Q3 2025, -$451.0 million for Q2 2025, and -$420.3 million during Q1 2025.